Friday, December 9, 2011
08:30-10:00 |
OPENING SESSION |
| Chairpersons | J.H.Lang, China (Honorary Chairman) C.Q. Zhou, China G. Lu, China Z.J. Chen, China Z. Ben Rafael, Israel |
| 08:30-08:35 | Opening remarks |
| Experts views on where our field is heading | |
| 08:35-08:55 | Stem Cells and Their Significance in Gynecology C. De Geyter, Switzerland |
| 08:55-09:15 | Sperm fitness testing and experimental IVF on integrated Lab-on-a-Chip devices J. Cheng, K. Mitchelson, China |
09:15-10:00 |
WHEN WILL LAPAROSCOPY REPLACE ALMOST ALL LAPAROTOMIES? |
| Capsule | Video-Laparoscopy is developing fast, covering an ever growing number of operations and disciplines. Prof. Nezhat, often referred to as a "Wizard" in Laparoscopy, will present his personal view, an odyssey of science technology and will explain where Video-Laparoscopy is heading and if this technology will ever put to rest all laparotomies, and in his words: "The objectives of the lecture are, to motivate the younger physicians, bring hope to their work and education and encouragement in their careers" C.R. Nezhat, USA |
| 10:00-10:20 | Coffee break |
10:20-11:50 |
MILD STIMULATION FOR IVF |
| Capsule | Proponents of monofollicular stimulation claim that this is the way for IVF, especially in an era of single embryo transfer (SET). Opponents, in turn, suggest that pregnancy rates are too low to make it a viable alternative. Can we agree on what direction we should take? |
| Chairpersons | S.A. Carson, USA Z.J. Chen, China |
| 10:20-11:05 |
Debate: Should We Always Strive to Use Mild Stimulation for IVF?
Proposition: Mild stimulation IVF combined with single embryo transfer (SET) should be the method used for IVF S. Daya, Canada Opposition: Results are too low and dropout rates are too high to make it a viable option! N. Gleicher, USA Discussion |
| 11:05-11:50 |
Debate: Preventing all Multiple Pregnancies by Systematic Single Embryo Transfer (SET) for all?
Yes: G.N. Huang, China No: N. Gleicher, USA Discussion |
| Objectives | To acquire knowledge about the following:
|
| 11:50-12:10 | Poster viewing |
12:10-13:40 |
PREIMPLANTATION GENETIC SCREENING (PGS): WHAT IS NEXT?
|
| Capsule | Preimplantation genetic diagnosis (PGD) was initially introduced to identify single gene defects, but evolved under the acronym "PGS" (preimplantation genetic screening) into a tool to detect embryo aneuploidy. The proposed goal was to improve pregnancy rates in IVF, and reduce spontaneous abortion rates, Thus far, studies indicate that in order to compensate for the risks involved, improvement of more than 10% is needed. The current question is does the future of PGS lie in the technical improvements? Can we keep refining the method, using newer technologies such as comparative genomic hybridization (CGH), and embryo diagnosis via trophectoderm biopsy? |
| Chairpersons | S. Daya, Canada M. von Wolff, Switzerland (TBC) C. De Geyter, Switzerland (TBC) |
| 12:10-12:55 |
Debate: PGS is an Experimental Tool that Should be Banned from Routine Clinical Use!
Proposition: PGS, as currently practiced, is associated with inferior results and should not be routinely offered N. Gleicher, USA Opposition: The beneficial effects of preimplantation genetic diagnosis for aneuploidy support extensive clinical applications Guangxiu Lu, China (TBC) |
| 12:55-13:15 | Can CGH in PGS be the answer for the inefficiencies in PGS? K.W.R. Choy, Hong Kong |
| 13:15-13:40 | Meiotic contribution to aneuploidy Y.W. Xu, China |
| Objectives | Upon completion of this debate, the audience will learn:
|
| 13:40-14:30 | Lunch break |
14:30-16:00 |
IN VITRO MATURATION (IVM)
|
| Capsule | IVM is becoming more effective,but will it ever replace IVF? Benefits, risks and pitfalls of the procedure |
| Chairpersons | C. De Gytner, Switzerland Hefeng Huang, China |
| 14:30-15:15 |
Debate: Will IVM Ever Replace Standard IVF?
Yes: Results of IVM are comparable to standard IVF with or without stimulation M. Benkhalifa, France No: IVM does not offer any advantage over current IVF practice X. Liang, China Discussion |
| 15:15-15:40 | IVM for PCOS patients M. Benkhalifa, France |
| 15:40-16:00 | What have we learned from oocyte donation programs! O. Coll, Spain |
| Objectives | Upon completion of this session, the audience will have acquired:
|
| 16:00-16:30 | Coffee break |
16:30-18:00 |
IMPROVING RESULTS IN IVF |
| Capsule | Improving the results of IVF requires that each aspect of the treatment from the clinical elements of ovarian stimulation, to laboratory work and quality assurance, to awareness of infection and risk, stimulation and embryo transfer techniques be boosted. Disagreement exists only over basic procedures and also over the universal use of ICS |
| Chairpersons | O. Coll, Spain C.Q. Zhou, China Z.J. Chen, China |
| 16:30-16:55 | Quality Management in IVF B. Imthurn, Switzerland |
| 16:55-17:15 | The standardization and safety of ART G.X. Lu, China |
| 17:15-17:40 | Impact of viral infection on reproductive function O. Coll, Spain |
| 17:40-18:00 | Is ICSI overused? J. Liu, China |
| Objectives: | Upon completion of this session, the audience will have learned:
|
| 18:30-19:45 | Special entertaining performance of “Snakes, Bugs and Us” By “Skip” Granai, MD, USA |
Saturday, December 10, 2011
08:30-10:00 |
ASSESSMENT AND TREATMENT OF OVARIAN RESERVE |
| Capsule | Diminished ovarian reserve (DOR) remains a common, frustrating and Under diagnosed condition. Lack of criteria for diagnosis makes it difficult to assess and compare prevalence of diagnosis and results of treatments.Questions have been raised as to whether DOR even lends itself to treatment and, if so, whether treatment regimen results differ |
| Chairpersons | S. Carson, USA C. De Gytner, Switzerland M. Benkhalifa, France |
| 08:30-08:55 |
Has Anti-Müllerian Hormone (AMH) Become Essential in Assessing Ovarian Reserve?
S. Daya, Canada |
| 08:55-09:40 |
Debate: Can Diminished Ovarian Reserve be Treated Effectively?
Yes: N. Gleicher, USA No: S. Daya, Canada Discussion |
| 09:40-10:00 | 2000 IU of hCG in responders does not affect the outcome of IVF Y. Kuang, China |
| Objectives | Upon completion of these debates, the audience will have learned the following:
|
| 10:00-10:20 | Coffee break |
10:20-11:50 |
POLYCYSTIC OVARIAN SYNDROME (PCOS) AND OHSS |
| Capsule | Controversy over the management of Polycystic Ovarian Syndrome (PCOS) patients continues. These patients tend to have ovarian hyperstimulation syndrome (OHSS) and multiple pregnancies when stimulated. The debate here is what should be the first step of treatment? Should we start with stimulation +IUI which can’t prevent multiples or should we persue surgical techniques that can provide temporary relief and success, albeit at a possible price, or should we just proceed with IVF? |
| Chairpersons | E. Manalo, Philippines S. Daya, Canada H.F. Huang, China |
| 10:20-11:05 |
Debate: Treating Anovulatory PCOS Patients: What Should be the First Choice?
Gonodotropins versus clomiphene citrate as first line therapy to improve pregnancy rate
S. Daya, Canada Ovulation induction +IUI and IVF N. Gleicher, USA Discussion |
| PCOS in Filipino women E. Manalo, Philippines |
|
| 11:30-11:50 | Do PCOS patients have delayed ovarian aging? Z. Ben Rafael, Israel |
| Objectives | To acquire knowledge about the following:
|
| 11:50-12:10 | Poster viewing |
12:10-13:40 |
HOT CONTROVERSIES ON ART CLINICAL ISSUES |
| Moderators | Z. Ben Rafael, Israel C.Q. Zhou, China |
| Discussants | Z.J. Chen, China S. Daya, Canada N. Gleicher, USA S. Carson, USA M. Benkhalifa, France |
Round Table Discussion and Expert Opinions on:
|
| 13:40-14:30 | Lunch break |
14:30-16:00 |
BASIC ASPECTS OF ART |
| Chairpersons | X.C. Yu, China J. Zhang, China S.A. Carson, USA |
| 14:30-14:55 | Multipotent adult germ line stem cells: New therapeutic hope? R. Schwartz, USA |
| 14:55-15:15 | Genetic imprinting and embryonic development H.F. Huang, China |
| 15:15-15:40 | The value of sperm morphology Z.W. Chen, China |
| 15:40-16:00 | Embryonic stem cell therapeutic potential: Is the future here? Y.L. Ma, China |
| 16:00-16:30 | Coffee break |
16:30-18:00 |
ONCOFERTILITY: THE PRESERVATION OF FUTURE GENERATIONS |
| Capsule | About 75% of children treated for cancer are expected to be long term survivors, and hence fertility preservation is one of the aims of the treatment that also allows for normal life experience. The multiple modalities of treatment which include modified surgery, alternative modalities of chemotherapies, can help preserve fertility. Newer techniques, even if still experimental like gamete freezing, in vitro maturation (IVM) and IVF, expand the choices. Fertility saving surgery can be performed in certain cancer cases, however no clear guidelines or limit are set, and the age in which these procedures should be offered is controversial |
| Chairpersons | Z.J. Chen, China M. von Wolff, Switzerland O. Coll, Spain |
| 16:30-17:00 | Should fertility be saved in the infants and adolescence with malignancies? S. Carson, USA |
| 17:00-17:30 | Should fertility be spared in women with ovarian malignancies? S. Granai, USA |
| 17:30-17:00 | Prophylactic surgery in BRCA gene patients: What should be done and when? R. Moore, USA |
Sunday, December 11, 2011
08:30-10:00 |
Rescue ICSI |
||||||||
| Capsule | Is rescue ICSI is effective if fertilization -failure after conventional IVF? Some say yes , the most important thing is to choose the rif it is done early enough, within the “rescue window” before oocyte aging | ||||||||
| Chairperson | C. Zhou, China | ||||||||
|
Debate:
|
|||||||||
|
Debate:
|
|||||||||
| 10:00-10:20 | Coffee break |